On January 2, 2025, N. Anthony Coles, a director at Regeneron Pharmaceuticals, acquired 166 shares of common stock through a grant. The transaction was executed at a price of $0 per share, indicating it was likely part of a compensation package or incentive plan.Following this acquisition, Coles' direct ownership in Regeneron increased to 1,559 shares. The transaction was reported as completed, suggesting immediate vesting or transfer of the shares. This grant aligns with common practices in the biotech industry to incentivize and retain key personnel through equity-based compensation.

On January 2, 2025, N. Anthony Coles, a director at Regeneron Pharmaceuticals, acquired 166 shares of common stock through a grant. The transaction was executed at a price of $0 per share, indicating it was likely part of a compensation package or incentive plan.Following this acquisition, Coles' direct ownership in Regeneron increased to 1,559 shares. The transaction was reported as completed, suggesting immediate vesting or transfer of the shares. This grant aligns with common practices in the biotech industry to incentivize and retain key personnel through equity-based compensation.